The effect of Atorvastatin in combination to Tenofovir in the treatment of Hepatitis B
Phase 2
- Conditions
- iver Disease.Toxic liver disease with hepatitis, not elsewhere classifiedK71.6
- Registration Number
- IRCT20110621006852N2
- Lead Sponsor
- Ghoum University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Patients with active hepatitis B that are candidates for anti-viral therapy
Viral load greater than 100,000 per ml
patients with elevated ALT
Exclusion Criteria
All patients with severe kidney failure.
Patients who use suppressor drugs for immune system.
Patients with acquired or congenital immune deficiencies.
Patients who have had a history of taking statins or any other antiviral medicines in the last six months.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral load. Timepoint: At the beginning of the trial and then once every three months interval. Method of measurement: realtime PCR.
- Secondary Outcome Measures
Name Time Method